The global overactive bladder treatment market is projected to reach USD 4.19 billion by 2022 from USD 3.63 billion in 2017, at a CAGR of 2.9%. Factors such as the development of innovative intravesical therapies, aggressive marketing by pharma companies leading to rising awareness on bladder overactivity, and favorable demographics are driving the growth of this market.
In this report, the market is segmented on the basis of pharmacotherapy, disease type, and region. On the basis of pharmacotherapies, the global overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. Anticholinergics are further classified into solifenacin, darifenacin, fesoterodine, tolterodine, trospium, oxybutynin, and other anticholinergics.
Get PDF Brochure Here : http://www.marketsandmarkets.com/pdfdownload.asp?id=219938791
The neurostimulation and BOTOX treatment segments are expected to register the highest CAGR during the forecast period, whereas, solifenacin takes the largest share in the market. Higher efficacy along with no side effects and long-term results are fueling the growth of the neurostimulation and BOTOX segments.
Based on disease type, the market is segmented into idiopathic bladder overactivity and neurogenic bladder overactivity. The neurogenic bladder overactivity segment is further classified into Parkinson’s disease, stroke, multiple sclerosis (MS), spinal cord injury (SCI), and other disorders (tumors, heavy metallic poisoning, infection to the brain or spinal cord, degenerative disorders, and diabetic neuropathy). In 2017, the idiopathic bladder overactivity treatment segment is expected to account for the largest share. Whereas, the neurogenic overactive bladder treatment segment is expected to grow at the highest rate during the forecast period. The increasing prevalence of degenerative disorders (such as Parkinson’s, multiple sclerosis, and Alzheimer’s) and increasing incidence of stroke are likely to result in a growth in the number of neurogenic bladder overactivity patients.
Geographically, the overactive bladder treatment market in the Rest of Asia-Pacific (RoAPAC) region is expected to register the highest CAGR during the forecast period. Favorable demographics, high OAB prevalence and low awareness on the condition, growing focus of major pharmaceutical manufacturers in this developing geography, and rapid increase in generic drug production are the primary drivers for the growth of the Asia-Pacific bladder overactivity treatment market.
Emerging markets such as India, South Korea, Singapore, China, Brazil, and South Africa have a higher potential for the growth in the overactive bladder treatment market owing to the low awareness on the disease and low penetration of the treatments on the disease. Factors such as demographic changes, increasing disposable incomes (which increases the willingness to spend on advanced overactive bladder treatments), and growing pharmerging industry leading to aggressive marketing of products are expected to boost the adoption of overactive bladder treatment products in these countries.